PL3544981T3 - Związki benzodiazolium jako inhibitory enac - Google Patents

Związki benzodiazolium jako inhibitory enac

Info

Publication number
PL3544981T3
PL3544981T3 PL17807900T PL17807900T PL3544981T3 PL 3544981 T3 PL3544981 T3 PL 3544981T3 PL 17807900 T PL17807900 T PL 17807900T PL 17807900 T PL17807900 T PL 17807900T PL 3544981 T3 PL3544981 T3 PL 3544981T3
Authority
PL
Poland
Prior art keywords
benzodiazolium
compounds
enac inhibitors
enac
inhibitors
Prior art date
Application number
PL17807900T
Other languages
English (en)
Polish (pl)
Inventor
Clive Mccarthy
Jonathan David HARGRAVE
Duncan Alexander HAY
Thomas Beauregard SCHOFIELD
Naomi WENT
Original Assignee
Enterprise Therapeutics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterprise Therapeutics Limited filed Critical Enterprise Therapeutics Limited
Publication of PL3544981T3 publication Critical patent/PL3544981T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/12Mucolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL17807900T 2016-11-22 2017-11-22 Związki benzodiazolium jako inhibitory enac PL3544981T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1619694.1A GB201619694D0 (en) 2016-11-22 2016-11-22 Compounds
PCT/GB2017/053499 WO2018096325A1 (fr) 2016-11-22 2017-11-22 Composés de benzodiazolium en tant qu'inhibiteurs d'enac
EP17807900.0A EP3544981B1 (fr) 2016-11-22 2017-11-22 Composés de benzodiazolium en tant qu'inhibiteurs d'enac

Publications (1)

Publication Number Publication Date
PL3544981T3 true PL3544981T3 (pl) 2021-12-20

Family

ID=57993838

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17807900T PL3544981T3 (pl) 2016-11-22 2017-11-22 Związki benzodiazolium jako inhibitory enac

Country Status (21)

Country Link
US (3) US10941149B2 (fr)
EP (1) EP3544981B1 (fr)
JP (1) JP6980014B2 (fr)
KR (1) KR102517273B1 (fr)
CN (1) CN110214141B (fr)
AU (1) AU2017364308B2 (fr)
BR (1) BR112019009864A2 (fr)
CA (1) CA3043132A1 (fr)
DK (1) DK3544981T3 (fr)
EA (1) EA039607B1 (fr)
ES (1) ES2890226T3 (fr)
GB (1) GB201619694D0 (fr)
HU (1) HUE055692T2 (fr)
IL (1) IL266745B (fr)
MA (1) MA46878A (fr)
MX (1) MX2019005934A (fr)
PL (1) PL3544981T3 (fr)
PT (1) PT3544981T (fr)
TW (1) TWI756305B (fr)
WO (1) WO2018096325A1 (fr)
ZA (1) ZA201902710B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) * 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
GB201717051D0 (en) 2017-10-17 2017-11-29 Enterprise Therapeutics Ltd Compounds
GB201801355D0 (en) 2018-01-26 2018-03-14 Enterprise Therapeutics Ltd Compounds
GB201808093D0 (en) 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds
GB201908453D0 (en) 2019-06-12 2019-07-24 Enterprise Therapeutics Ltd Compounds for treating respiratory disease
BR112021025079A2 (pt) 2019-06-12 2022-02-15 Tmem16A Ltd Composto, uso de um composto, método para o tratamento ou profilaxia de doenças e condições afetadas pela modulação de tmem16a e composição farmacêutica
GB201910608D0 (en) * 2019-07-24 2019-09-04 Enterprise Therapeutics Ltd Compounds
CN116745267A (zh) 2020-12-11 2023-09-12 跨膜蛋白16A有限公司 用于治疗呼吸系统疾病的苯并咪唑衍生物

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858614B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US6903105B2 (en) 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
US20050090505A1 (en) 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
EP1670475A4 (fr) 2003-08-18 2009-04-15 Parion Sciences Inc Bloqueurs du canal sodique a base de pyrazinoylguanidine alaphatique
KR20060037450A (ko) 2003-08-18 2006-05-03 패리온 사이언스 인코퍼레이티드 사이클릭 피라지노일구아니딘 나트륨 채널 차단제
US7064129B2 (en) 2003-08-18 2006-06-20 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US7309716B2 (en) * 2003-10-28 2007-12-18 Vertex Pharmaceuticals Incorporated Benzimidazoles useful as modulators of ion channels
US7399766B2 (en) 2004-08-18 2008-07-15 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
EP2457901A1 (fr) * 2005-03-14 2012-05-30 High Point Pharmaceuticals, LLC Dérivés de benzazole, compositions et procédés d'utilisation en tant qu'inhibiteurs de secrétase B
US7807834B2 (en) 2005-08-03 2010-10-05 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526240D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
WO2008124491A1 (fr) 2007-04-03 2008-10-16 Parion Sciences, Inc. Composes de pyrazinoylguanidine destines a etre utilises en tant que modulateurs de gout
PL2155721T3 (pl) 2007-05-07 2011-07-29 Novartis Ag Związki organiczne
WO2009019506A1 (fr) 2007-08-03 2009-02-12 Astrazeneca Ab Sulfonamides hétérocycliques ayant une activité antagoniste de edg-1
WO2009074575A2 (fr) 2007-12-10 2009-06-18 Novartis Ag Composés organiques
TWI432198B (zh) 2008-02-26 2014-04-01 Parion Sciences Inc 多芳香族鈉通道阻斷劑
CA2723938A1 (fr) 2008-05-13 2009-11-19 Novartis Ag Derives d'acide 3,5-diamino-6-chloro-pyrazine-2-carboxylique et leur utilisation comme bloqueurs de canal du sodium epithelial pour le traitement de maladies des voies respiratoires
JP2011522860A (ja) 2008-06-10 2011-08-04 ノバルティス アーゲー 上皮性ナトリウムチャネルブロッカーとしてのピラジン誘導体
WO2011028740A1 (fr) 2009-09-03 2011-03-10 Glaxo Group Limited Bloqueurs du canal enac
WO2011079087A1 (fr) 2009-12-23 2011-06-30 Glaxo Group Limited Bloqueurs du canal enac
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
TW201204353A (en) * 2010-06-08 2012-02-01 Vertex Pharma Formulations of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
GEP20186880B (en) 2011-11-02 2018-07-25 Ingelheim International Gmbh Boehringer 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
US8859559B2 (en) 2011-12-20 2014-10-14 Boehringer Ingelheim International Gmbh Substituted pyrazines and their use in the treatment of disease
PL2855435T3 (pl) 2012-05-29 2018-10-31 Parion Sciences, Inc. Amidy o strukturze podobnej do dendrymerów, wykazujące aktywność blokerów kanałów sodowych, do leczenia zespołu suchego oka i innych chorób śluzówki
US8841309B2 (en) 2012-09-24 2014-09-23 Boehringer Ingelheim International Gmbh Substituted pyrazines and their use in the treatment of disease
US9593084B2 (en) 2012-12-17 2017-03-14 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
WO2014099673A1 (fr) 2012-12-17 2014-06-26 Parion Sciences, Inc. Composés 3,5-diamino -6-chloro-n-(n- (4-phénylbutyl)carbamimidoyl) pyrazine-2-carboxamide
CA2896686A1 (fr) 2012-12-17 2014-06-26 Parion Sciences, Inc. Composes 3,5-diamino -6-chloro-n-(n- (4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide
EP2991981B1 (fr) 2013-04-30 2017-03-01 Boehringer Ingelheim International GmbH Composés de diaminopyrazine, médicaments contenant lesdits composés, leur utilisation et leurs procédés de préparation
KR20160054460A (ko) 2013-07-02 2016-05-16 더 캘리포니아 인스티튜트 포 바이오메디칼 리써치 낭성 섬유증의 치료를 위한 화합물
JP6449870B2 (ja) 2013-07-08 2019-01-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肺および気道の疾患を処置するための上皮性ナトリウムチャネルの阻害剤としてのアミロライド型化合物
WO2015007519A1 (fr) 2013-07-15 2015-01-22 Boehringer Ingelheim International Gmbh Nouveaux composés benzimidazolium
WO2015007517A1 (fr) 2013-07-15 2015-01-22 Boehringer Ingelheim International Gmbh Nouveaux composés de benzimidazolium tétra-substitués et penta-substitués
JP6461948B2 (ja) 2013-07-15 2019-01-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規5−置換ベンゾイミダゾリウム化合物
EP3030555B1 (fr) 2013-08-08 2019-01-30 Boehringer Ingelheim International GmbH Nouveaux composés d'amide de pyrazine
EP3245199B1 (fr) * 2015-01-12 2020-01-01 Boehringer Ingelheim International GmbH Composés de benzimidazolium substitués utiles pour le traitement de maladies respiratoires
WO2016113169A1 (fr) 2015-01-12 2016-07-21 Boehringer Ingelheim International Gmbh Composés de benzimidazolium tétra et pentasubstitués, utiles dans le traitement de maladies respiratoires
JP6847838B2 (ja) 2015-01-12 2021-03-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 上皮ナトリウムチャネル阻害剤としての2−(ピラジン−2−イルカルボニルアミノメチル)ベンズイミダゾリウム化合物
US9932324B2 (en) 2015-01-12 2018-04-03 Boehringer Ingelheim International Gmbh Substituted benzimidazolium compounds useful in the treatment of respiratory diseases
JP6620171B2 (ja) 2015-08-20 2019-12-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規縮環フェノキシアセトアミド
MX2018002006A (es) 2015-08-20 2018-06-19 Boehringer Ingelheim Int Benzamidas apareadas novedosas.
GB201610854D0 (en) * 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) * 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds

Also Published As

Publication number Publication date
JP2019535747A (ja) 2019-12-12
IL266745A (en) 2019-07-31
BR112019009864A2 (pt) 2019-08-27
EP3544981A1 (fr) 2019-10-02
MA46878A (fr) 2019-10-02
KR20190084076A (ko) 2019-07-15
PT3544981T (pt) 2021-09-23
TWI756305B (zh) 2022-03-01
JP6980014B2 (ja) 2021-12-15
DK3544981T3 (da) 2021-09-20
US10941149B2 (en) 2021-03-09
GB201619694D0 (en) 2017-01-04
WO2018096325A1 (fr) 2018-05-31
CN110214141A (zh) 2019-09-06
US20190315757A1 (en) 2019-10-17
HUE055692T2 (hu) 2021-12-28
EA201991253A1 (ru) 2019-11-29
US20210147432A1 (en) 2021-05-20
US20240067653A1 (en) 2024-02-29
KR102517273B1 (ko) 2023-04-03
TW201833111A (zh) 2018-09-16
ES2890226T3 (es) 2022-01-18
CN110214141B (zh) 2022-05-31
EA039607B1 (ru) 2022-02-16
CA3043132A1 (fr) 2018-05-31
IL266745B (en) 2021-12-01
US11739094B2 (en) 2023-08-29
AU2017364308A1 (en) 2019-05-23
AU2017364308B2 (en) 2021-03-11
EP3544981B1 (fr) 2021-06-23
MX2019005934A (es) 2019-11-12
ZA201902710B (en) 2021-10-27

Similar Documents

Publication Publication Date Title
HUS2400003I1 (hu) Kináz inhibitorként alkalmas vegyületek
HUE059324T2 (hu) Heterociklusos vegyületek, mint PI3K-gamma inhibitorok
IL266745A (en) Benzodiazolonium compounds as enac inhibitors
HK1257500A1 (zh) 包含尿石素化合物的組合物
GB201513481D0 (en) Inhibitor compounds
GB201505658D0 (en) Inhibitor compounds
HK1249901B (zh) 用於抑制ror-gamma-t的化合物
HK1253576A1 (zh) 作為mnk抑制劑的吡咯並嘧啶化合物
HK1257565A1 (zh) 作為htra1抑制劑的新型三氟甲基丙酰胺衍生物
HK1257567A1 (zh) 作為htra1抑制劑的新型二氟酮酰胺衍生物
HK1252767A1 (zh) 作為eaat3抑制劑的吡唑-吡啶衍生物
GB201613945D0 (en) Compounds useful as kinase inhibitors
GB201522245D0 (en) Compounds useful as kinase inhibitors
GB201520189D0 (en) Compound for use
GB201522453D0 (en) Inhibitor compounds
GB201500644D0 (en) Inhibitor compounds